3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
13
Urogenital Neoplasms
2
Prostatic Diseases
2
Neoplasms by Site
2
Neoplasms
2
Genital Neoplasms, Male
2
Breast Neoplasms
2
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer
1
Male Urogenital Diseases
1
Genital Diseases, Male
1
Castrate-resistant Prostate Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Prostate Cancer
1
Adenocarcinoma
1
Interventions
pembrolizumab
1
olaparib
1
lenvatinib
1
enzalutamide
1
belzutifan
1
Prednisone
1
Etoposide
1
Docetaxel
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Metastatic Castration-Resistant Prostate Cancer
×
Abiraterone Acetate
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled